Pirfenidone for the treatment of idiopathic pulmonary fibrosis

Bibliography

• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824
   PubMed Web of Science ®Google Scholar
• Luppi F, Spagnolo P, Cerri S, et al. The big clinical trials in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012;18:428-32
   PubMed Web of Science ®Google Scholar
• Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel randomised trial. Ann Intern Med 2013;158:641-9
   PubMed Web of Science ®Google Scholar
• Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of IPF: the randomized controlled MUSIC trial. Eur Respir J 2013; [Epub ahead of print]
   Google Scholar
• Xaubet A, Ancochea J, Bollo E, et al. Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Arch Bronconeumol 2013;49:343-53
   PubMedGoogle Scholar
• Behr J, Günther A, Ammenwerth W, et al. German Guideline for Diagnosis and Management of idiopathic Pulmonary Fibrosis. Pneumologie 2013;67:81-111
   PubMedGoogle Scholar
• Idiopathic pulmonary fibrosis guidelines. Danish Society of Respiratory Medicine. Available from: www.lungemedicin.dk [Last accessed 29 August 2013]
   Google Scholar
• Position statement from the Irish Thoracic Society on the treatment of idiopathic pulmonary fibrosis. Available from: http://www.irishthoracicsociety.com/images/uploads/ITS%20Statement%20Final.pdf [Last accessed 28 August 2013]
   Google Scholar
• Care programs for idiopathic pulmonary fibrosis. Swedish Society for Pulmonary Medicine. Available from: http://www.slmf.se/sites/default/files/VPIL [Last accessed 28 August 2013]
   Google Scholar
• Pirfenidone for treating idiopathic pulmonary fibrosis. National Institute for Health and Clinical Excellence. Available from: http://guidance.nice.org.uk/TA/Wave23/25/FAD/FinalAppraisalDetermination/pdf/English [Last accessed 28 August 2013]
   Google Scholar
• Potts J, Yogaratnam D. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis. Ann Pharmacother 2013;47:361-7
   PubMed Web of Science ®Google Scholar
• Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011;20:120; 85-97
   PubMedGoogle Scholar
• Giri SN, Leonard S, Shi X, et al. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 1999;18:169-77
   PubMedGoogle Scholar
• Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, et al. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 2010;3:16
   PubMedGoogle Scholar
• Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol Lung Cell Mol Physiol 1999;276:L311-18
   PubMed Web of Science ®Google Scholar
• Nakazato H, Oku H, Yamane S, et al. A novel antifibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur J Pharmacol 2002;446:177-85
   PubMed Web of Science ®Google Scholar
• Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590:400-8
   PubMed Web of Science ®Google Scholar
• Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-a, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002;446:167-76
   PubMed Web of Science ®Google Scholar
• Tian XL, Yao W, Guo ZJ, et al. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycin. Chin Med Sci J 2006;21:145-51
   PubMedGoogle Scholar
• Ozes ON, Blatt LM. Development of a high throughput collagen assay using a cellular model of idiopathic pulmonary fibrosis. Chest 2006;130:230S
   Google Scholar
• Nayayama S, Mukae H, Sakamoto M, et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 2008;82:210-17
   PubMedGoogle Scholar
• Hisatomi K, Mukae H, Sakamoto N. Pirfenidone inhibits TGF-beta-1 induced overexpression of collagen type I and heat shock protein 47 in A549 cells. BCM Pulm Med 2012;12:24
   PubMed Web of Science ®Google Scholar
• Jackson RM, Gomez Marin O. Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: review of preclinical science and recent clinical trials. Trasplant Res Risk Manag 2011;3:55-63
   Google Scholar
• Shi S, Wu J, Chen H, et al. Single and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 2007;47:1268-76
   PubMed Web of Science ®Google Scholar
• Huang NY, Ding L, Wang J, et al. Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under Fed conditions. Drug Res (Sturg) 2013;63(8):388-95
   PubMedGoogle Scholar
• Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antiacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol ther 2009;22:279-85
   PubMed Web of Science ®Google Scholar
• InterMune. Esbriet_(pirfenidone): EU summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pro duct_Information/human/002154/WC500103049.pdf [Last accessed 28 August 2013]
   Google Scholar
• Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol 1997;52:77-8
   PubMed Web of Science ®Google Scholar
• Raghu G, Johnson CJ, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med 1999;159:1061-9
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9
   PubMed Web of Science ®Google Scholar
• Azuma A, Tanaguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Kondo H, Ebina M, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011;12:93
   PubMedGoogle Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med 2011;5:473-81
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010;9:CD003134
   Google Scholar
• Costabel U, Albera C, Bradfor W, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Eur Respir J 2012;40(Suppl 56):511s
   Google Scholar
• Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013;107:1431-7
   PubMed Web of Science ®Google Scholar
• Bonella F, Wessendorf TE, Costabel U. Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis. Dtsch Med Wochenschr 2013;138:518-23
   PubMed Web of Science ®Google Scholar
• Inoue Y, Azuma A, Ogura T, et al. All-case post-marketing surveillance of pirfenidone in Japan: clinical characteristics, efficacy and safety profile in > 1300 patients with idiopathic pulmonary fibrosis (IPF). European Respiratory Society Annual Congress 2013; Session 345
   Google Scholar
• Iwasawa T, Ogura T, Sakai F, et al. CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. Eur J Radiol 2012; Epub ahead of print
   PubMedGoogle Scholar
• Jiang CH, Huang H, Liu J, et al. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One 2012;7(10):e47024
   PubMed Web of Science ®Google Scholar
• Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002;76:234-42
   PubMed Web of Science ®Google Scholar
• O´Brien K, Troendle J, Gochuico BR, et al. Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 2011;103:128-34
   PubMedGoogle Scholar
• InPharm. First idiopathic pulmonary fibrosis drug approved (on line). Available from: http://www.inpharm.com/news/149931/intermune-idiopathic-pulmonary-fibrosis-esbriet-pirfenidone [Last accessed 28 August 2013]
   Google Scholar